Growing Role of In Vivo Studies in Pre-Clinical Drug Development

The Evolution of Pre-Clinical Testing

Pre-clinical drug development has evolved significantly over the past few decades. While in vitro studies using cell and tissue cultures were once the primary method for assessing drug safety and efficacy, researchers have increasingly turned to in vivo models using live animal subjects. This shift reflects a recognition that whole organism studies offer insights that cannot be gleaned from isolated cells and tissues alone. Living systems are vastly more complex, with interactions between multiple organs, systems and physiological processes. In vivo testing allows researchers to evaluate how investigational drugs are absorbed, distributed, metabolized and excreted within a living body. It also provides a means to assess potential toxicity at both the organ and system levels.

The Rise of Contract Research Organizations

Managing in vivo pre-clinical studies presents unique operational challenges due to the live animal component. This has fueled the growth of contract research organizations (CROs) specializing in nonclinical drug development services using animal models. Often referred to as in vivo CROs, these providers have the dedicated facilities, equipment, personnel and technical expertise required for handling live test subjects. They can take responsibility for all aspects of an in vivo study on behalf of pharmaceutical and biotech clients, from test material management and dose administration to clinical observations, sample collection and analytical testing. This allows drug developers to avoid the steep upfront capital investment of building and maintaining in-house vivarium facilities, as well as the costs of ongoing regulatory compliance. It also gives them access to specialized technical skills that may not be justified for an individual internal program.

Key Advantages of Using In Vivo CROs

There are several clear advantages that in vivo CROs provide over an internal approach to pre-clinical animal testing:

Dedicated Expertise - CROs employ veterinarians, technicians and other professionals with extensive experience in GLP-compliant in vivo study conduct. Their staff have developed deep skills in administering treatments, measuring endpoints and managing logistical complexities.

Regulatory Compliance - Maintaining compliance with global regulations like GLP can require considerable resources. CROs are set up specifically for this purpose, freeing sponsors from ongoing associated costs and responsibilities.

Scalability - CROs can quickly adjust their staffing levels and cage space availability to accommodate varying project needs and timelines. Clients gain flexibility without committing long-term to physical infrastructure.

Enhanced Data Integrity - Purpose-built central laboratory facilities and standardized operating procedures at CROs help ensure consistent, high-quality data generation across studies.

Specialized Models and Services - CROs offer access to disease models, sophisticated analytical techniques like imaging, and other capabilities beyond what most sponsors could support individually.

Risk Mitigation - Any issues involving animal welfare, facility operation or regulatory compliance become the CRO's responsibility when studies are outsourced.

Time and Cost Savings - With established workflows and economies of scale, well-run CROs can typically complete in vivo programs more quickly and cost-effectively compared to sponsor-managed internal resources.

Areas of In Vivo CRO Expertise

In vivo CROs support the full scope of nonclinical drug development through specialized services:

Toxicology - Single dose, repeat dose and long term toxicity screening in rodents and non-rodents as well as TK, in vitro metabolism and ADME profiling.

Pharmacology - In vivo efficacy models for various therapeutic areas including oncology, metabolic disease, inflammation and more.

Pharmacokinetics - In vivo absorption, distribution, metabolism and excretion studies, typically in rodents initially to derive PK parameters.

Safety Pharmacology - Cardiovascular, respiratory and CNS monitoring to identify potential safety liabilities early.

Disease Models - Sophisticated large animal and specialized rodent models that emulate human pathologies for translational research.

Biomarker Discovery and Validation - In vivo studies to identify, characterize and clinically qualify novel biomarkers.

Formulation and Drug Delivery - Evaluating bioavailability, stability and device/formulation performance using animal models.

Bioanalytical Services - Robust LCMS/MS methods for accurate quantitation of compounds and metabolites in biological matrices.

Outsourcing to expert CRO partners allows pharmaceutical and biotech sponsors to access world-class in vivo testing capacity and data without heavy on-site infrastructure investments.

Get This Report in English Language: In Vivo CRO

Get This Report in Japanese Language: インビボCRO

Get This Report in Korean Language: 생체 내 CRO

About Author:

Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)